Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report sent to investors on Friday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ:ADXS opened at $0.03 on Friday. The company has a market capitalization of $1.15 million, a PE ratio of 0.00 and a beta of 1.70. The stock has a fifty day moving average of $0.04 and a 200-day moving average of $0.08. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.